We are live on ! Find out more
RA

Rosalind Advisors Portfolio holdings

AUM $249M
1-Year Est. Return 80.12%
This Fund
S&P 500
This Quarter Est. Return
+40.59%
1 Year Est. Return
+80.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$121M
AUM Growth
–
Cap. Flow
+$480M
Cap. Flow %
395.45%
Top 10 Hldgs %
61.9%
Holding
30
New
30
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
LYRA
LYRA THERAPEUTICS INC
LYRA
+$6.84M
2
XERS icon
Xeris Biopharma Holdings
XERS
+$6.54M
3
ATXS
Astria Therapeutics
ATXS
+$6.24M
4
OPTN
OptiNose
OPTN
+$5.94M
5
VRDN icon
Viridian Therapeutics
VRDN
+$5.69M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 98.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QQQ icon
26
PUT
Invesco QQQ Trust
QQQ
$450B
$602K 0.5%
+900,000
New +$342M
TLPH icon
27
Talphera
TLPH
$70.1M
$558K 0.46%
+758,966
New +$483K
XBI icon
28
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.3B
$465K 0.38%
+500,000
New +$37.1M
GERN icon
29
Geron
GERN
$860M
$422K 0.35%
+200,000
New +$389K
TNXP icon
30
Tonix Pharmaceuticals
TNXP
$161M
$363K 0.3%
+282
New +$454K
1
2

Similar funds

TAM
Tabor Asset Management New York $249M AUM 48.59% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
MC
Mount Capital London, United Kingdom $248M AUM 4.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
GWS
Greykasell Wealth Strategies Danville, California $248M AUM 22.08% 1-Year Est. Return
SCM
Segra Capital Management Palm Beach, Florida $248M AUM 65.61% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return

Rosalind Advisors's Q4 2023 Portfolio in Review

Q4 2023 is the first quarter with a 13F filing on record for Rosalind Advisors, which disclosed 30 positions worth $121M. Its ten largest holdings account for 62% of the portfolio.

Its largest position is LYRA THERAPEUTICS INC: 37,774 shares worth $9.9M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets.

  • Rosalind Advisors's largest Q4 2023 buy was LYRA THERAPEUTICS INC: 37,774 shares worth $9.9M.
  • Rosalind Advisors's ten largest holdings make up 62% of its $121M portfolio in Q4 2023.
  • Rosalind Advisors disclosed 30 positions in Q4 2023, its first 13F filing on record.

Based on Rosalind Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.